Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Recurrent Loss of NFE2L2 Exon 2 Is a Mechanism for Nrf2 Pathway Activation in Human Cancers.

Cell reports - 6 Sept 2016

Goldstein Leonard D, Lee James, Gnad Florian, Klijn Christiaan, Schaub Annalisa, Reeder Jens, Daemen Anneleen, Bakalarski Corey E, Holcomb Thomas, Shames David S, Hartmaier Ryan J, Chmielecki Juliann, Seshagiri Somasekar, Gentleman Robert, Stokoe David

Abstract excerpt

The Nrf2 pathway is frequently activated in human cancers through mutations in Nrf2 or its negative regulator KEAP1. Using a cell-line-derived gene signature for Nrf2 pathway activation, we found that some tumors show high Nrf2 activity in the absence of known mutations in the pathway. An analysis of splice variants in oncogenes revealed that such tumors express abnormal transcript variants from the NFE2L2 gene...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Survival
Share to Gene Expression Regulation, Neoplastic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genome, Human

Share to Kelch-Like ECH-Associated Protein 1

Share to Neoplasms

Share to NF-E2-Related Factor 2

Share to Reproducibility of Results

Share to Sequence Deletion

Source

Identifiers

PMID: 27568559
DOI: 10.1016/j.celrep.2016.08.010

Genes

KEAP1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Recurrent Loss of NFE2L2 Exon 2 Is a Mechanism for Nrf2 Pathway Activation in Human Cancers.PMID 27568559Read ↗

KEAP1/NFE2L2 Pathway Signature Outperforms KEAP1/NFE2L2 Mutation Status and Reveals Alternative Pathway-Activating Mutations in NSCLC.Semantic proximity Read ↗

A catalogue of somatic NRF2 gain-of-function mutations in cancerSemantic proximity Read ↗

Functional polymorphisms in Nrf2: implications for human disease.Semantic proximity Read ↗

NRF2 and the Ambiguous Consequences of Its Activation during Initiation and the Subsequent Stages of TumourigenesisSemantic proximity Read ↗

Specific cancer types and prognosis in patients with variations in the KEAP1-NRF2 system: A retrospective cohort study.Semantic proximity Read ↗

A core NRF2 gene set defined through comprehensive transcriptomic analysis predicts selective drug resistance and poor multi-cancer prognosisSemantic proximity Read ↗

Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy.Semantic proximity Read ↗

NFE2L2/KEAP1 Mutations Correlate with Higher Tumor Mutational Burden Value/PD-L1 Expression and Potentiate Improved Clinical Outcome with Immunotherapy.Semantic proximity Read ↗

KEAP1/NRF2 (NFE2L2) mutations in NSCLC - Fuel for a superresistant phenotype?Semantic proximity Read ↗

NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer.Semantic proximity Read ↗

NRF2 pathway activation and SPP1⁺TREM2⁺ macrophages drive chemoradiotherapy resistance in esophageal squamous cell carcinomaSemantic proximity Read ↗

Molecular mechanisms and systemic targeting of NRF2 dysregulation in cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.